How Big Can Merck's Keytruda Be In Lung Cancer?
Shares of Merck are up 4% on an otherwise down day for pharma stocks. There are three reasons:
Quarterly results that beat analyst expectations. Earnings per share were $0.85, compared to consensus of $0.74; Sales were $9.4 billion compared to expectations of $9 billion.
More importantly: Januvia, Merck's best-selling product, cleared an important safety bar from a clinical trial. This could give Januvia, which generated $1.39 billion by itself and as a combination pill with a generic this quarter, an advantage over competitors.
Merck's new cancer drug, Keytruda, which works by unleashing the immune sys...
Source: Forbes.com Healthcare News - April 28, 2015 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news
TECOS: No Increase in HF Hospitalization With SitagliptinTECOS: No Increase in HF Hospitalization With Sitagliptin
Top-line results of the TECOS cardiovascular outcomes trial with sitagliptin indicate no increased risk of heart failure with the drug, Merck has announced. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 28, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Cardiovascular Outcomes With Merck's Januvia: No Better Or Worse Than Conventional Care
Late Monday afternoon Merck released the top line results of TECOS, the cardiovascular outcomes trial with its blockbuster diabetes drug Januvia (sitagliptin). The company said that the trial "achieved its primary endpoint of non-inferiority for the composite cardiovascular (CV) endpoint." Merck announced only one additional detail: "Among secondary endpoints," they reported, "there was no increase in hospitalization for heart failure in the sitagliptin group versus placebo." (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 27, 2015 Category: Pharmaceuticals Authors: Larry Husten Source Type: news
Merck's diabetes drug Januvia succeeds in heart safety trial
(Reuters) - Merck and Co's diabetes drug Januvia achieved the main goal of a long-awaited heart safety study, according to preliminary results released by the drugmaker on Monday, likely removing a cloud of uncertainty from its biggest product. (Source: Reuters: Health)
Source: Reuters: Health - April 27, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Merck Announces the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Met Primary Endpoint
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Trial Evaluating Cardiovascular Outcomes with
Sitagliptin (TECOS) of Merck’s DPP-4 inhibitor, JANUVIA®
(sitagliptin), achieved its primary endpoint of non-inferiority for the
composite cardiovascular (CV) endpoint. Among secondary endpoints, there
was no increase in hospitalization for heart failure in the sitagliptin
group versus placebo.
Language:
...
Source: Merck.com - Product News - April 27, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
Liraglutide and Sitagliptin in Type 2 DiabetesLiraglutide and Sitagliptin in Type 2 Diabetes
Does liraglutide offer greater glycemic contol and weight reduction than sitagliptin in clinical practice? International Journal of Clinical Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 10, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
TECOS Study With Sitagliptin (Januvia) to Be Reported at ADA TECOS Study With Sitagliptin (Januvia) to Be Reported at ADA
The results of the long-awaited cardiovascular-outcomes trial with Merck's type 2 diabetes treatment, the DPP-4 inhibitor sitagliptin, will be revealed at the American Diabetes Association meeting. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 5, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Merck Sales Down 4%; Profit Beats Forecasts
The pharmaceutical company’s earnings beat expectations, however, helped by sales of the diabetes drug Januvia and revenue in emerging markets. (Source: NYT)
Source: NYT - October 27, 2014 Category: American Health Authors: By KATIE THOMAS Tags: Company Reports Drugs (Pharmaceuticals) Idenix Pharmaceuticals Inc IDIX NASDAQ Merck & Company Inc MRK NYSE Bayer AG BAYRY Other OTC Source Type: news
T1DM remission with sitagliptin
Type 1 diabetes mellitus (T1DM) is a chronic disease characterized by the autoimmune destruction of pancreatic β-cells in genetically susceptible subjects, which results in absolute insulin deficiency. Several agents used to reestablish immunological tolerance over the past few years have successfully prevented and even reverted T1DM in nonobese diabetic mice; however, these outcomes have not been achieved in humans.
Lima-Martinez et al. report on a case of a 19-year old male on intensive insulin treatment as he presented with glutamic acid decarboxylase (GAD) antibody positive and diabetic ketoacidos...
Source: Society for Endocrinology - October 21, 2014 Category: Endocrinology Source Type: news
New Weekly DPP-4 Inhibitor Effective in Diabetics in Japan New Weekly DPP-4 Inhibitor Effective in Diabetics in Japan
In a phase 3 study in Japanese type 2 diabetes patients, the novel once-weekly DPP-4 inhibitor omarigliptin was as effective as daily sitagliptin for glycemic control and was generally well tolerated. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 29, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Merck reports observational data of Januvia and metformin combination for type 2 Diabetes
Merck has reported data from an observational study that assessed the differences in initiated insulin therapy in patients with type 2 diabetes taking a combination of Januvia (sitagliptin) and metformin, as well as sulphonylurea and metformin. (Source: Drug Development Technology)
Source: Drug Development Technology - September 17, 2014 Category: Pharmaceuticals Source Type: news
Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes
Dateline City:
WHITEHOUSE STATION, N.J.
Omarigliptin significantly reduced HbA1c levels compared to placebo
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the presentation of the first data from the Phase 3
clinical development program for omarigliptin, Merck’s investigational
once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. In a
study in Japanese patients, omarigliptin pr...
Source: Merck.com - Corporate News - September 17, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Byetta Lawsuit News: Bernstein Liebhard LLP Notes British...
The Firm is actively investigating Januvia and Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis and other serious injuries after taking either of the...(PRWeb August 15, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12098941.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 16, 2014 Category: Pharmaceuticals Source Type: news
Byetta Lawsuit News: New Order Establishes Deposition Protocol For...
The Firm is investigating Byetta lawsuits and other legal claims that allege incretin mimetics like Byetta, Januvia and Victoza caused patients to develop pancreatic cancer, pancreatitis or thyroid...(PRWeb August 10, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12083571.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 10, 2014 Category: Pharmaceuticals Source Type: news
The Sitagliptin Saga: More Evidence for Possible HF Hazard The Sitagliptin Saga: More Evidence for Possible HF Hazard
Initiating the drug in patients with diabetes who already have HF may elevate the risk of subsequent HF hospitalization, suggests a retrospective analysis from a national US cohort. Heartwire (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 3, 2014 Category: Consumer Health News Tags: Cardiology News Source Type: news
